Search Bar & Filters
Found 7 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the efficacy and safety of Imeroprubart in adults with active Chronic Inflammatory Demyelinating Polyneuropathy CIDP, a neurological disorder. This Phase 2b, multi-center, randomized, double-blind, placebo-controlled study focuses on adult participants who meet specific diagnostic criteria for CIDP or its variants. The study is sponsored by Immunovant Sciences GmbH and aims to understand how well Imeroprubart helps prevent relapses and improves disability and muscle strength in this population. Participants will receive either Imeroprubart or a matching placebo by subcutaneous injection once weekly. The initial treatment period lasts 24 weeks, with a further extension period of 52 weeks for continued evaluation. Imeroprubart is given as a dose 1 injection under the skin weekly during these periods, while the placebo group receives matching injections during the first 24 weeks. Throughout the study, participants will be regularly assessed for relapse status, disability scales, grip strength, muscle strength scores, and functional impairment from baseline up to Week 24. These assessments include standardized clinical scales such as the Inflammatory Rasch-Built Overall Disability Scale I-RODS and Medical Research Council Sum Score MRC-SS. Safety and efficacy are closely monitored, with the primary outcome focusing on the proportion of participants remaining relapse-free by Week 24. The total study duration extends until May 2030.
Actively Recruiting
Central Line-Associated Bloodstream Infections CLABSIs are a serious problem in U.S. hospitals, leading to higher death rates, longer hospital stays, and increased costs. This research evaluates whether a machine learning ML model that predicts possible CLABSI risk can help Infection Preventionists IPs reduce infection rates compared to usual practices. The study is a prospective, multi-center, cluster-randomized trial conducted in 20 hospitals with the highest CLABSI rates. In this trial, hospitals are split into early and late groups. Early hospitals get access to the ML model via a daily dashboard that flags high-risk patients. Infection Preventionists use this information to provide targeted education and recommend best practices for central line care, including line removal when appropriate. The model was built using extensive patient data and predicts infection risk with high accuracy. The control hospitals continue with routine clinical practice without access to the model during the study period. Participants are hospitalized adults with central lines, and the model scores patients daily if their line has been in place for over 48 hours. Researchers monitor CLABSI rates per 1,000 central line-days, central line removals within 48 hours of alerts, positive blood culture rates, and IP intervention frequencies. Safety outcomes such as pneumothorax and hemorrhage are also tracked. The study duration is about five months with interim and final analyses planned to assess the impact of providing the ML model to Infection Preventionists.
Actively Recruiting
Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.
Actively Recruiting
Researchers are collecting whole blood and serum samples from adults diagnosed with untreated Hepatocellular Carcinoma HCC and from individuals undergoing surveillance for HCC without the disease. The purpose is to use these samples to develop and validate the Helio multi-analyte blood test, which aims to detect liver cancer by analyzing DNA methylation and protein markers. Participants include those with cirrhosis or at risk of HCC, representing major liver disease causes such as alcoholic steatohepatitis, hepatitis B or C, non-alcoholic fatty liver disease, and genetic conditions like hemochromatosis. Participants fall into three groups those recently diagnosed with untreated HCC confirmed by CT scan, MRI, or biopsy those confirmed negative for HCC by CT or MRI and those confirmed negative by ultrasound. The ultrasound-negative group will have a follow-up ultrasound 5 to 9 months after enrollment to reconfirm the absence of HCC. Blood samples collected will be used to study the performance of selected DNA methylation and protein markers for liver cancer diagnosis. Participants are screened based on medical history and recent imaging results to confirm eligibility. Assessments include blood collection and imaging studies, with additional follow-up imaging for some. Researchers will measure the sensitivity and specificity of the blood test within 1 to 9 months and investigate the effects of interfering substances, reference ranges, and sample stability. The study is observational, with no treatment administered, and is expected to continue through December 2028.
Actively Recruiting
Researchers are evaluating the efficacy, safety, and tolerability of SPN-817 as an additional treatment in adults with focal onset seizures who have not responded to at least two anti-seizure medications. This Phase 2, double-blind, randomized, placebo-controlled study involves multiple centers and compares SPN-817 to a placebo in adults aged 18 to 70 years taking 1 to 4 anti-seizure medications and experiencing at least four seizures during a six-week screening period. Participants will be randomly assigned in a 21 ratio to receive either SPN-817 3.0 to 4.0 mg twice daily or a placebo. The study includes a titration period lasting 8 to 10 weeks during which an antiemetic medication, ondansetron, is taken prophylactically before each dose to manage potential side effects. After reaching the target dose, participants enter a maintenance period lasting 14 weeks. Ondansetron may be used as needed during this phase. After completing the maintenance period, participants may join a separate open-label study for continued SPN-817 treatment or undergo a tapering period of up to four weeks, followed by a safety follow-up phone call. Throughout the trial, participants will keep electronic seizure diaries, and the research team will monitor seizure frequency and treatment-emergent adverse events. The main measurement is the percent change in seizure frequency during the maintenance period compared to baseline. Additional evaluations include the proportion of participants with significant seizure reduction and seizure-free intervals. The total study involvement includes the screening, titration, maintenance, tapering, and follow-up periods, with assessments to track safety and treatment effects.
Actively Recruiting
This research evaluates patients with metastatic HER-2-positive breast cancer who are at risk of heart damage from trastuzumab-based treatments. It includes two groups one observational group of patients taking beta blockers, ACE inhibitors, or ARBs alongside their cancer therapy, and a smaller randomized group studying whether carvedilol may prevent heart side effects from chemotherapy. The study aims to understand how often heart problems occur and identify factors that predict these risks. Participants are assigned to one of three groups those taking carvedilol twice daily, those receiving no additional treatment, and those already on beta blockers, ARBs, or ACE inhibitors who are observed without intervention. Treatments or observation continue for up to 108 weeks, with repeated cycles every 12 weeks unless disease progresses or side effects occur. The study also collects blood samples and performs heart function imaging to explore biomarkers and measure heart strain. During the study, participants undergo regular echocardiograms every 12 weeks to assess heart function and strain. Researchers monitor for cardiac events, interruptions in cancer therapy, and adherence to medication. Blood samples are taken to bank for future studies. The main outcome is time until the first sign of cardiac dysfunction over about two years. Safety and side effects of treatments are also tracked, and participants are followed until the study ends in 2031.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the impact of telehealth self-management coaching sessions on the quality of life of pancreatic cancer survivors and their family caregivers. Pancreatic cancer patients often face numerous symptoms from the disease and its treatment, which can negatively affect their quality of life. This study aims to address unmet needs by providing support in managing physical symptoms, emotional, social, and spiritual well-being through remote coaching. Participants will be divided into two groups one group will attend telehealth self-management coaching sessions lasting 40 to 60 minutes every other week for a total of six sessions over three months. The other group will receive standard care. Both patients and their family caregivers are included in the coaching sessions, which are designed to help with symptom management and caregiver support. During the study, participants will complete questionnaires to report on quality of life, symptom severity, psychological distress, caregiving burden, and overall survival. These assessments occur at the start of the study and at 3 and 6 months after randomization. The study monitors enrollment, session completion, participant experiences, and follow-up rates over up to six months, with the total study duration lasting three months for the coaching sessions and follow-up assessments continuing thereafter.